APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 3mg capsule blister pack

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

rivastigmine hydrogen tartrate, Quantity: 4.8 mg

Pieejams no:

Arrotex Pharmaceuticals Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

rivastigmine hydrogen tartrate

Zāļu forma:

Capsule

Kompozīcija:

Excipient Ingredients: iron oxide red; microcrystalline cellulose; Gelatin; iron oxide yellow; stearic acid; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Ievadīšanas:

Oral

Vienības iepakojumā:

14, 28, 112, 56

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Produktu pārskats:

Visual Identification: Hard gelatine calsule with orange, opaque body and orange opaque cap. Imprinted "APO R3" in black ink, white to off white fill.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2010-07-27